Pier Paolo Piccaluga

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
  2. ncbi Novel FLT3 point mutation in acute myeloid leukaemia
    Pier Paolo Piccaluga
    , University of Bologna, S Orsola-Malpighi Hospital, Italy
    Lancet Oncol 4:604. 2003
  3. ncbi Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR28. 2003
  4. ncbi Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:731-3. 2004
  5. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  6. ncbi Advances in the treatment for haematological malignancies
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Expert Opin Pharmacother 7:721-32. 2006
  7. ncbi Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified
    Pier Paolo Piccaluga
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Lancet Oncol 6:440. 2005
  8. ncbi Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
  9. ncbi First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
  10. ncbi Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003

Detail Information

Publications70

  1. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  2. ncbi Novel FLT3 point mutation in acute myeloid leukaemia
    Pier Paolo Piccaluga
    , University of Bologna, S Orsola-Malpighi Hospital, Italy
    Lancet Oncol 4:604. 2003
  3. ncbi Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR28. 2003
  4. ncbi Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:731-3. 2004
    ..In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL...
  5. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  6. ncbi Advances in the treatment for haematological malignancies
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Expert Opin Pharmacother 7:721-32. 2006
    ..Although these novel therapies are beginning to fulfil their promise, continued research efforts are needed to determine the optimal role of these strategies in haemato-oncology...
  7. ncbi Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified
    Pier Paolo Piccaluga
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Lancet Oncol 6:440. 2005
  8. ncbi Imatinib mesylate in the treatment of hematologic malignancies
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Molecular Pathology Laboratory, Unit of Hematopathology, Via Massarenti, 9 40138 Bologna, Italy
    Expert Opin Biol Ther 7:1597-611. 2007
    ..In this article, the authors review the evidence which led to imatinib approval in the treatment of several of the above mentioned diseases...
  9. ncbi First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Res 28:987-90. 2004
    ..Larger prospective studies are now warranted in order to better define the possible role of this regimen in the treatment of elderly AML patients...
  10. ncbi Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Haematologica 88:1221-8. 2003
    ..Other genes that have been implicated at the rearrangement breakpoint are GR6 and RPN1 (both on 3q21). The aim of this study was to investigate the expression of the EVI1 fusion genes in AML patients with 3q21q26 syndrome...
  11. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    , Hematology and Hematopathology Units, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
    ..The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials...
  12. ncbi Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer 110:1178-86. 2007
    ..It also has demonstrated promising efficacy in Ph+ ALL but is still being evaluated in phase 2 trials. In this article, the authors reviewed current knowledge on novel tyrosine-kinase inhibitors in adult Ph+ ALL patients...
  13. ncbi Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC
    Michele Bianchini
    , University of Bologna, Via Massarenti No. 9, 40138 Bologna, Italy
    Clin Chem 49:1642-50. 2003
    ....
  14. ncbi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
    ..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...
  15. ncbi Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  16. ncbi Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  17. ncbi Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Italy
    Haematologica 88:ECR37. 2003
  18. ncbi Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leuke
    Ilaria Iacobucci
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 114:2159-67. 2009
    ....
  19. ncbi CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified
    Anna Gazzola
    Department of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 64:83-7. 2011
    ..CDKN1B/p27, a critical regulator of cell cycle and proliferation, has been suggested to be involved in T cell lymphomagenesis. This study aimed to evaluate the possible occurrence of CDKN1B/p27 aberrations in PTCL/NOS...
  20. ncbi Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Unit, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Blood 117:3596-608. 2011
    ..In conclusion, our study provided substantial insights on the pathobiology of BLs, by offering novel evidences that may be relevant for its classification and possibly future treatment...
  21. ncbi Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  22. ncbi Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission
    Michele Malagola
    , University of Bologna, Italy
    Haematologica 89:ECR25. 2004
  23. ncbi Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Lancet Oncol 9:352-8. 2008
    ....
  24. ncbi Prognostic markers in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Curr Hematol Malig Rep 5:222-8. 2010
    ..The validation process for several models, including clinical-pathological and molecular models, is now ongoing...
  25. ncbi Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Leuk Lymphoma 45:1791-5. 2004
    ..VOD was documented in 1 case. We conclude that GO is effective as a single agent in AML and myeloid sarcomas. Further data are required to clarify the possible correlation between GO administration and occurrence of bleeding...
  26. ncbi Biology and treatment of follicular lymphoma
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Unit, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Expert Rev Hematol 2:533-47. 2009
    ..Novel approaches, including stem cell transplantation, monoclonal antibodies and innovative agents, should be then considered for improving long-term results...
  27. ncbi Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Res 67:10703-10. 2007
    ..Our study provides new relevant information on AILT biology and new candidates for possible therapeutic targets such as PDGFRA (platelet-derived growth factor alpha) and VEGF...
  28. ncbi Pathobiology of hodgkin lymphoma
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, 40126 Bologna, Italy
    Adv Hematol 2011:920898. 2011
    ..Treatments adjusted to the pathobiological characteristics of the tumor in at-risk patients have been proposed and are on the way to being applied...
  29. ncbi BCL10 down-regulation in peripheral T-cell lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Hum Pathol 43:2266-73. 2012
    ..In conclusion, BCL10 was commonly down-regulated in peripheral T cell lymphomas, suggest the T-cell receptor signaling cascade for future characterization...
  30. ncbi Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive
    Claudio Agostinelli
    Haematopathology Section, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Histopathology 59:679-91. 2011
    ..To revise 25 cases selected from Karl Lennert's personal archive (21) and Bologna and Frankfurt Registries (four) because of cytological similarities...
  31. ncbi Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method
    Ilaria Iacobucci
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Haematologica 93:1814-21. 2008
    ..Shorter isoforms, which lack the amino-terminal domain that mediates sequence-specific DNA binding, exert a dominant negative effect and inhibit the ability of longer heterodimer partners to bind DNA...
  32. ncbi Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma
    Stefano Ascani
    Unit of Hematopathology, , Bologna University, Bologna, Italy
    J Clin Oncol 22:953-4. 2004
  33. ncbi Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples
    Claudio Agostinelli
    Departments of Haematology and Clinical Oncology L and A Seràgnoli, Pathology and Haematopathology Unit, St Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Appl Immunohistochem Mol Morphol 18:561-72. 2010
    ..We describe the newly generated DAK-PAX5 monoclonal antibody raised against a fixation-resistant epitope of the human PAX5/BSAP molecule...
  34. ncbi Peripheral T-cell lymphoma classification: the matter of cellular derivation
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 4:415-25. 2011
    ....
  35. ncbi Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
    Silvia Buonamici
    , University of Bologna, Italy
    Blood 99:443-9. 2002
    ..12% might indicate the patient is in a curable state. If confirmed, such thresholds could open the way to a new phase in post-CR therapeutic decision making for patients with inv(16) AML...
  36. ncbi Lymphoma classification: the quiet after the storm
    Stefano A Pileri
    Department of Haematology and Oncological Sciences L and A Seragnoli, Bologna University School of Medicine, Bologna, Italy
    Semin Diagn Pathol 28:113-23. 2011
    ..The present review aims to analyse future perspectives after the fourth edition of the WHO Classification released in 2008...
  37. ncbi Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome
    Stefano Ascani
    Unit of Hematopathology, , Bologna University, St. Orsola Hospital, Bologna, Italy
    Haematologica 89:EIM07. 2004
  38. ncbi New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia
    Giovanni Martinelli
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 2:297-303. 2009
    ..New therapeutic approaches are now available, such as dasatinib, nilotinib and bosutinib, and we highlight those that may be applicable to the treatment of adult BCR-ABL1-positive ALL...
  39. ncbi Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature
    Valentina Tabanelli
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Section, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Med Case Reports 5:218. 2011
    ..abstract:..
  40. ncbi Pathobiology of ALK-negative anaplastic large cell lymphoma
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Pediatr Rep 3:e5. 2011
    ..The main histological findings are illustrated as well as the phenotypic, molecular and clinical characteristics. Finally, the biological rationale for possible innovative targeted therapies is presented...
  41. ncbi Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins
    Stefano A Pileri
    Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
    Am J Pathol 162:243-53. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations...
  42. ncbi Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Curr Oncol Rep 13:407-15. 2011
    ..The real role of FDG-PET scanning requires prospective studies, and it is hoped that this may allow the de-escalation of radiation therapy accordingly to yield reliable prognostic information...
  43. ncbi Pathobiology of acute lymphoblastic leukemia
    Stefania Paolini
    Molecular Pathology Laboratory, Hematology Section, Department of Haematology and Oncology L and A Sernignoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:124-34. 2011
    ..Similarly, the use of FLT3 inhibitors in mixed lineage leukemia-positive cases, gamma-secretase inhibitors in T-ALL, novel TKI, and monoclonal antibodies may represent a successful approach in the future...
  44. ncbi Primary cutaneous lymphomas: a reprisal
    Alessandro Pileri
    Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:214-33. 2011
    ..Our aim is to evaluate the commonest types of PCL analysing the clinical characteristics, histology, phenotype, molecular biology, prognosis and therapy...
  45. ncbi Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:234-44. 2011
    ..For example, the nuclear factor-KB pathway and platelet-derived growth factor receptor inhibition may represent 2 options to be tested in clinical trials...
  46. ncbi Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays
    Pier Luigi Zinzani
    Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Haematologica 90:341-7. 2005
    ..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression...
  47. ncbi Follicular lymphoma: still Six characters in search of an author?
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 52:1655-67. 2011
    ..This review was inspired by the reappraisal of Professor Lennert's personal archive that represents a unique legacy for the entire scientific community...
  48. ncbi Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Opin Biol Ther 6:1011-22. 2006
    ..In addition, preliminary experiences with novel tyrosine kinase inhibitors in imatinib-resistant Ph+ ALL are discussed...
  49. ncbi Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  50. ncbi Molecular profiling of aggressive lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Haematopathology Unit, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Adv Hematol 2012:464680. 2012
    ..In this paper, the authors based on their own experience and the most updated literature review, the main concept on molecular profiling of aggressive lymphomas...
  51. ncbi The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis
    Stefano A Pileri
    Lymphoma Study Group, Institute of Haematology and Clinical Oncology, Bologna University, Italy
    Haematologica 90:293. 2005
  52. ncbi Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomach
    Stefano Aldo Pileri
    Pathologic Anatomy, Clinical and Pathology Lymphoma Units, , Bologna University, Italy
    Haematologica 87:ECR40. 2002
  53. ncbi Granulocytic sarcoma of main biliary ducts
    Stefano Ascani
    Unit of Haematopathology, , Bologna University, St. Orsola Hospital, Bologna, Italy
    Br J Haematol 121:534. 2003
  54. ncbi Babesia infection in Italy
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology, S Orsola-Malpighi Hospital, University of Bologna, Italy
    Lancet Infect Dis 4:212. 2004
  55. ncbi Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
    Michele Malagola
    Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Br J Haematol 136:87-95. 2007
    ..In this setting of patients, large prospective randomised studies should be planned...
  56. ncbi The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients
    Pier Paolo Piccaluga
    Haematologica 89:1269-71. 2004
    ..000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004)...
  57. ncbi Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors
    Giulia De Falco
    Department of Human Pathology and Oncology, University of Siena, Italy
    Blood 110:1301-7. 2007
    ..In conclusion, these data suggest that, as RBL2/p130 modulates the expression of target genes, which are important for cell growth and viability, its inactivation may be relevant for the occurrence of BL...
  58. ncbi Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Michele Malagola
    Blood 105:904; author reply 905. 2005
  59. ncbi Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
    Simona Soverini
    J Clin Oncol 24:e51-2. 2006
  60. ncbi No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
    Giuseppe Visani
    Department of Hematology, H San Salvatore, Pesaro, Italy
    Leuk Lymphoma 45:1361-4. 2004
    ....
  61. ncbi Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases
    Michele Malagola
    Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Eur J Haematol 81:354-63. 2008
    ..The intensification of induction chemotherapy and the use of non-conventional drugs such as fludarabine are considered responsible for the increased risk of infections...
  62. ncbi An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab
    Giuseppe Visani
    Department of Hematology, San Salvatore Hospital, Pesaro, Italy
    Leuk Lymphoma 47:2542-6. 2006
    ....
  63. ncbi Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
    Pier Paolo Piccaluga
    Eur J Haematol 72:302-3. 2004
  64. ncbi Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease
    Giuseppe Visani
    Haematologica 88:ELT15. 2003
  65. ncbi Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia
    Pier Paolo Piccaluga
    Cancer Genet Cytogenet 151:85-6. 2004
  66. ncbi FLT3 inhibition as tailored therapy for acute myeloid leukemia
    Giovanni Martinelli
    Haematologica 88:4-8. 2003
  67. ncbi Expression of CD52 in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Haematologica 92:566-7. 2007
    ....
  68. ncbi Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely
    Giovanni Martinelli
    Haematologica 89:495-7. 2004
    ..We now update the molecular follow-up of our patients, also presenting the therapeutic management of these patients...
  69. ncbi The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
    Bronno van der Holt
    Department of Hematology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:2646-54. 2005
    ..The role of strategies aimed at inhibitory P-gp and other drug-resistance mechanisms continues to be defined in the treatment of patients with AML...
  70. ncbi From chronic lymphocytic leukemia to Hodgkin's disease: a case of prognostically favorable transformation
    Pier Luigi Zinzani
    Leuk Res 26:775-6. 2002